Skip to main
  1. Stocks
  2. Prime Medicine Inc
  3. Forecast
PRME

PRME Stock Forecast & Price Target

PRME Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Prime Medicine is attractive fundamentally because its pipeline is beginning to convert a broad prime-editing platform into multiple, liver-targeted clinical programs with clear catalysts, including PM577a in Wilson disease and PM647 in AATD, both with initial data expected in 2027. The company also has meaningful external validation from PM359 in CGD, where human data showed durable restoration of immune function, and it retains additional upside from a potential PM359 BLA submission in 1H27 and a possible PRV that could monetize at roughly $200M based on recent sales. Financially, 3Q26 collaboration revenue was $4.2M, net loss was $0.22 per share, and the November offering lifted pro forma liquidity to about $209.5M, which management expects to fund operations through 2027 and reduces near-term dilution risk.

Bears say

Prime Medicine is viewed negatively because its $109 mm cash balance as of 30 June, down from $191.4M at end-FY25, appears only sufficient to fund two programs into 2027 while high cash burn keeps financing risk elevated. The outlook is further pressured by substantial clinical and regulatory uncertainty, including patient recruitment hurdles, gene-editing safety concerns, and no certainty of approval or reimbursement in the US or elsewhere. Commercially, Wilson disease, AATD, and cystic fibrosis face competition and may not be as large as expected, while the company may still need additional capital before profitability, risking dilution.

PRME has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Prime Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

PRME Analyst Forecast & Price Prediction

Get the latest PRME stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PRME

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Prime Medicine Inc (PRME) Forecast

Analysts have given PRME a Buy based on their latest research and market trends.

According to 5 analysts, PRME has a Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Prime Medicine Inc (PRME)


PRME Analyst Forecast & Price Prediction

Get the latest PRME stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PRME

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PRME stock data and trends